Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus

NCT01962194 | Unknown

• 1 other identifier: RE403-HMO-CTIL
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators hypothesize that the emotional and cognitive areas of the Subthalamic Nucleus (STN) have distinct electrophysiological properties and that specific stimulation of these areas can influence the mental and the emotional state. Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) will be recruited over a period of two years. The patients will be enrolled in a prospective, open label, clinical trial and will be followed for one year. No randomization or blinding will be used in this study.

Conditions

Mapping the Limbic STN Using Neuronal Responses

Outcome Measures

Primary Outcomes (1)

• Mapping the limbic-associative STN in human using neuronal (single units & Local Field Potential (LFP)) responses to emotional stimuli during surgery and long term LFP recordings in PD and OCD patients

  Mapping the limbic-associative STN in human using neuronal (single units \& Local Field Potential (LFP)) responses to emotional stimuli during surgery and long term LFP recordings in Parkinson's diseae (PD) and Obsessive Compulsive Disorder (OCD) patients

  two years

Study Arms (1)

PD and OCD paients for DBS intervention

EXPERIMENTAL

Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.

Device: Deep Brain Stimulation

Interventions

Deep Brain Stimulation DEVICE

In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, "Activa PC+S", which has therapy equivalent to "Activa PC", and has a new sensing programmer.

PD and OCD paients for DBS intervention

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with PD who meet accepted criteria for DBS surgery:
• i. advanced idiopathic PD ii. long-term levodopa use that leads to decreased efficacy and increased incidence of adverse effects iii. normal cognitive function or mild-moderate cognitive decline (Addenbrooke's Cognitive Examination (ACE) \> 75 and the Frontal Assessment Battery (FAB) \> 10.
• Age 40-75 years
• Male or female
• Competent and willing to give written informed consent

You may not qualify if:

• A diagnosis of severe major depression disorder (MDD) with psychotic features
• Significant suicidal risk \[Hamilton Depression scale item 3 (suicide) \>2\]
• Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months
• Significant cognitive decline, as measured by Addenbrooke's Cognitive Examination (ACE) \< 75 and the Frontal Assessment Battery (FAB) \< 10.
• Significant cognitive impairment that would affect a participant's ability to give informed consent or provide interview or self-report data reliably
• Any clinically significant abnormality on preoperative MRI
• Any DBS contraindication, infection, coagulopathy, significant cardiac risk factors, or other medical risk factors for surgery
• Pregnant and/or woman of childbearing age not using effective forms of birth control
• Obsessive-compulsive disorder (OCD), diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID-IV)
• Presence of disabling severity, as assessed by a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 25
• Documented highly treatment refractory OCD; the documentation must demonstrate persistence of severe symptoms and impairment for 5 or more years despite both pharmacological and psychological treatments.
• Either drug free or on a stable drug regimen for at least 6 weeks before study entry
• General good overall health
• Age 20-70 years
• Male or female

Sponsors & Collaborators

• Hadassah Medical Organization: lead

Study Sites (1)

Hadassah Medical Center

Jerusalem, Israel, 91000, Israel

Location

MeSH Terms

Interventions

Deep Brain Stimulation

Intervention Hierarchy (Ancestors)

Electric Stimulation Therapy; Therapeutics; Surgical Procedures, Operative

Study Officials

• Renana Eitan, MD

  Hadassah Medical Organization

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Renana Eitan, MD

CONTACT

renanaeitan@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 25, 2013
• First Posted: October 14, 2013
• Study Start: December 1, 2013
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: October 14, 2013

Record last verified: 2013-06

Locations

IL (1)